The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients: Randomized controlled trial (RESPECT).
 
Masataka Sawaki
No Relationships to Disclose
 
Tsuyoshi Saito
No Relationships to Disclose
 
Shinichi Baba
No Relationships to Disclose
 
Kokoro Kobayashi
No Relationships to Disclose
 
Hiroaki Kawashima
No Relationships to Disclose
 
Michiko Tsuneizumi
No Relationships to Disclose
 
Noriko Sagawa
No Relationships to Disclose
 
Hiroko Bando
No Relationships to Disclose
 
Masato Takahashi
Speakers' Bureau - AstraZeneca Japan; Eisai
 
Miki Yamaguchi
No Relationships to Disclose
 
Tsutomu Takashima
Honoraria - Chugai Pharma; Eisai; Kyowa Hakko Kirin; Novartis; Takeda
 
Takahiro Nakayama
Honoraria - AstraZeneca Japan; Chugai Pharma; Novartis
 
Masahiro Kashiwaba
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Kirin Pharmaceuticals; Novartis; Pfizer
 
Toshiro Mizuno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Novartis; Ono Pharmaceutical
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Novartis; Taiho Pharmaceutical
 
Yutaka Yamamoto
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Nippon Kayaku; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca Japan; Chugai Pharma; Novartis
 
Naruto Taira
No Relationships to Disclose
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst)
 
Yukari Uemura
No Relationships to Disclose
 
Yasuo Ohashi
Leadership - EP-Cruse Co., Ltd; Statcom
Stock and Other Ownership Interests - Statcom
Honoraria - Chugai Pharma; Daiichi Sankyo; Kowa; Sanofi; Shionogi
Research Funding - Eisai (Inst); Yakult Pharmaceutical
Travel, Accommodations, Expenses - Yakult Pharmaceutical
 
Hirofumi Mukai
Honoraria - AstraZeneca Japan; Chugai Pharma; Pfizer; Taiho Pharmaceutical
Research Funding - Lilly Japan (Inst); Merck (Inst); Ono Pharmaceutical (Inst)